• CX-5461: Defining Selectivity and Mechanistic Precision in R

  2026-05-14

  Discover how CX-5461, a leading RNA polymerase I inhibitor, sets a new benchmark in cancer research with its unique selectivity and mechanistic insights. This article explores advanced applications, protocol precision, and evidence-driven guidance for maximizing its impact in translational oncology.

• Puromycin Aminonucleoside: Mechanistic Benchmarks for Podocy

  2026-05-13

  Puromycin aminonucleoside is a validated nephrotoxic agent for inducing podocyte injury and glomerular lesions in preclinical nephrotic syndrome research. As the aminonucleoside moiety of puromycin, it enables precise, reproducible models of proteinuria and FSGS. This article details its mechanisms, evidence, and best practices for integration into renal pathology workflows.

• Nystatin (Fungicidin): Antifungal Mechanisms & Research Use

  2026-05-13

  Nystatin (Fungicidin) is a polyene antifungal with robust activity against pathogenic yeasts, especially Candida species. Its efficacy and defined mechanism make it a gold standard for mycological research, with APExBIO providing a validated reagent for experimental reproducibility.

• DAPI Solution (1 mg/mL): Enhanced Nuclear Visualization Work

  2026-05-12

  APExBIO’s DAPI Solution (1 mg/mL) offers robust, high-contrast nuclear visualization and reliable apoptosis detection for fixed and permeabilized cells. This guide translates breakthrough findings in cancer research into optimized staining workflows, actionable troubleshooting, and advanced assay design for reproducible, publication-quality results.

• DiscoveryProbe Protease Inhibitor Library: Evidence & Workfl

  2026-05-12

  The DiscoveryProbe Protease Inhibitor Library enables high-throughput, reproducible protease inhibition studies across apoptosis, cancer, and infectious disease research. Its validated collection of 825 selective, cell-permeable inhibitors supports robust screening and mechanistic assays. APExBIO’s offering is distinguished by quality assurance protocols and workflow-ready formats.

• CBD Mitigates Orofacial Inflammatory Pain via Multi-Domain M

  2026-05-11

  This study demonstrates that cannabidiol (CBD) robustly alleviates both sensory and affective components of orofacial inflammatory pain in murine models. Through comprehensive behavioral and mechanistic analyses, the research reveals peripheral and central pathways—including endocannabinoid and serotonergic signaling—underlying CBD's effects, highlighting its translational promise for pain management.

• Ultrasound-Activated Nanoparticles for Lung Cancer: ONOO−-Me

  2026-05-11

  This study presents a multifunctional, pH-sensitive nanoparticle (M@DRSZ) that integrates chemotherapy and ultrasound-triggered sonodynamic therapy for lung cancer. By generating reactive oxygen and nitrogen species, including peroxynitrite, these nanoparticles induce apoptosis and modulate immune responses, offering a promising strategy for improving therapeutic efficacy.

• Neuroinflammatory Piezo2 Axis Drives Mechanical Allodynia in

  2026-05-10

  Liao et al. reveal how chronic trigeminal nerve root compression in rats initiates a neuroinflammatory cascade, amplifying pain via Ca2+-dependent signaling through the Piezo2/CGRP/SP axis. Their work establishes mechanistic links between ATP-driven intracellular pathways, neuropeptide upregulation, and peripheral sensitization, offering new molecular targets for trigeminal neuralgia research.

• Strategic Insights: Angiotensin II in Translational Vascular

  2026-05-09

  This thought-leadership article unpacks the mechanistic depth and translational value of Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) for vascular and fibrotic disease research. We bridge foundational GPCR biology to advanced modeling strategies, critically appraise experimental protocols, and situate APExBIO’s Angiotensin II within a competitive and evolving reagent landscape. By integrating recent findings on fibrotic signaling and referencing leading workflow resources, we offer actionable guidance to translational researchers seeking reproducible, high-impact results.

• 0.4% Trypan Blue Solution: Practical Guide for Cell Viabilit

  2026-05-08

  0.4% Trypan Blue Solution provides a robust, membrane-integrity-based method for distinguishing viable from non-viable cells in cell culture workflows. It is best suited for routine viability measurement, live/dead discrimination, and cell counting, but should not be used for diagnostic or clinical purposes. Researchers should follow best practices to ensure data reliability and avoid misinterpretation in complex or non-standard assays.

• Actinomycin D (A4448): Unveiling Epigenetic Control in Stem

  2026-05-08

  Explore how Actinomycin D enables precise dissection of transcriptional and epigenetic mechanisms in stem cell differentiation, expanding its value beyond classic cancer research. This comprehensive analysis highlights ActD's unique role as a transcriptional inhibitor in advanced mRNA stability and apoptosis studies.

• Lopinavir Identified as MERS-CoV Inhibitor in FDA Drug Scree

  2026-05-07

  de Wilde et al. conducted a high-throughput screen of FDA-approved compounds and identified Lopinavir (ABT-378) as one of four agents that inhibit MERS-CoV replication in cell culture at low-micromolar concentrations. This finding bridges HIV protease inhibitor research with emerging coronavirus therapeutics, providing a valuable foundation for drug repurposing strategies in infectious disease outbreaks.

• BIRB 796 (Doramapimod): Dual-Action Insights for Translation

  2026-05-07

  This thought-leadership article explores the unique, dual-action mechanism of BIRB 796 (Doramapimod) as a highly selective p38α MAPK inhibitor, emphasizing its role in modulating both kinase activity and phosphatase-mediated dephosphorylation. Integrating mechanistic evidence, protocol guidance, and workflow optimization, we provide translational researchers with actionable strategies for advancing inflammation research, apoptosis assays, and cytokine inhibition studies. Drawing on the latest structural biology and comparative landscape, this piece distinguishes itself by mapping the future of p38 MAPK pathway modulation beyond conventional paradigms.

• Caspase 3/7 Facilitate Autophagy and DNA Repair in Breast Ca

  2026-05-06

  This study reveals that caspase 3 and caspase 7 play a crucial, non-apoptotic role in promoting cytoprotective autophagy and DNA damage response during non-lethal stress in human breast cancer cells. The findings refine our understanding of cellular stress adaptation and highlight new molecular intersections for therapeutic exploration.

• 5-(N,N-dimethyl)-Amiloride: Translational Leverage in Vascul

  2026-05-06

  This article unpacks the mechanistic and translational relevance of 5-(N,N-dimethyl)-Amiloride (hydrochloride) as a precision Na+/H+ exchanger inhibitor. It bridges foundational ion transport biology with emerging strategies for endothelial injury research, highlighting the compound's value in experimental reproducibility, workflow optimization, and the quest for effective biomarkers in sepsis and cardiovascular pathology. Drawing on recent evidence, including the role of moesin as a biomarker for endothelial dysfunction, the discussion offers strategic guidance for translational researchers navigating the complexities of vascular biology.

16022 records 1/1069 page Next 12345 下5页 Last page